Eltrombopanolamine Tablets

[otw_shortcode_tabslayout tabs=”8″ tab_1_title=”Overview” tab_1_content=”Eltrombopagolamine is an orally bioavailable, small-molecule thrombopoietin (TPO) receptor agonist that interacts with the transmembrane structure of the human TPO receptor’s transmembrane structural domain to initiate a signaling cascade response that induces proliferation and differentiation of bone marrow progenitor cells.” tab_2_title=”Indications” tab_2_content=”Indicated in adults (≥18 years of age) with chronic immune (idiopathic) thrombocytopenia (ITP) who have not responded well to prior therapy with glucocorticoids, immunoglobulins, etc. to elevate platelet counts and reduce or prevent bleeding; eltrombopagolide should only be used in patients with ITP who are at increased risk of bleeding due to thrombocytopenia and clinical conditions ITP patients at increased risk of bleeding.” tab_3_title=”Dosage” tab_3_content=”For oral use, the recommended starting dose is 25 mg once daily, with dose adjustments as necessary to achieve and maintain a platelet count of ≥50,000/µL after initiation of therapy to reduce the risk of bleeding, not to exceed 75 mg daily.” tab_4_title=”Precautions” tab_4_content=”1. Clinical hematology and liver function tests should be monitored periodically during eltrombopagolide therapy. 2. Complete blood counts (CBC), including platelet counts and peripheral blood smears, should be assessed weekly during eltrombopagolide therapy until platelet count stability is achieved, and thereafter CBC, including platelet counts and peripheral blood smears, should be tested monthly. 3. Platelet count should be monitored at least once a week for 2-3 weeks after adjustment of eltromboprololamine dose. 4. Eltrombopagolamine should be used with caution in patients with hepatic and renal impairment, and liver and renal function should be monitored closely. After 4 weeks of treatment with 75 mg once-daily dose, if platelet count does not rise to a level sufficient to avoid clinically significant bleeding, stop eltrombopagolide treatment. ” tab_5_title=”Contraindications” tab_5_content=”Contraindicated in persons with hypersensitivity to eltrombopagolamine or any of the excipients.” tab_6_title=”Adverse Reactions” tab_6_content=”The most common adverse reactions at normal doses include headache, anemia, loss of appetite, insomnia, peripheral edema, and in severe cases, hepatotoxicity and thrombosis.” tab_7_title=”Interactions” tab_7_content=”1. Food: Eltrombopanolamine should be taken on an empty stomach (1 hour before or 2 hours after a meal), at least 2 hours before or at least 4 hours after the use of dairy products or mineral supplements containing multivalent cations (such as aluminum, calcium, iron, magnesium, selenium, and zinc), and should not be Eltrombopanolamine should not be crushed and mixed into food or liquid. (1) Eltrombopag ethanolamine can chelate with multivalent cations such as iron, calcium, magnesium, aluminum, selenium, and zinc. (2) The combination of etrapafen ethanolamine and HMG-CoA reductase (such as atorvastatin, fluvastatin, etc.) can lead to an increase in the latter’s blood concentration. (3) Combination of etrapafenamide with lopinavir/ritonavir (LPV/RTV) can lead to a decrease in the concentration of etrapafenamide. (4) Eltrombopag ethanolamine in combination with cyclosporine may affect the number of platelets. (5) The combination of eltrombopagolamine with OATP1B1 (e.g., methotrexate) and BCRP (e.g., topotecan and methotrexate) substrates may affect the in vivo course of the drug. ” tab_8_title=”Special Populations” tab_8_content=”1. Pregnant/Lactating Women (1) Pregnant Women and Women Who May Be Pregnant: The safety and effectiveness of the drug in pregnant women and women who may be pregnant have not been established; do not use if you are pregnant or think you may be pregnant. (2) Nursing women: The safety and efficacy of use during breastfeeding is not established. If you are breastfeeding, do not use eltrombopanolamine, and if you do need to use it, do not continue to breastfeed. 2. Elderly The data on the use of eltrombopagolide in patients aged ≥65 years are limited and safety is not established. If your doctor prescribes eltrombopagolide for you, please ensure that you use the drug strictly as prescribed by your doctor. The safety and efficacy of eltrombopagolamine in children has not been established. If your doctor prescribes eltrombopagolamine for children, please ensure that you use it strictly as prescribed by your doctor. 4. Patients with hepatic or renal impairment should use eltrombopagolamine with caution and closely monitor hepatic and renal function. “][/otw_shortcode_tabslayout]